Status:
COMPLETED
DDI Study Between Dorzagliatin and Rifampicin
Lead Sponsor:
Hua Medicine Limited
Conditions:
Drug Interaction
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.
Eligibility Criteria
Inclusion
- Body weight ≥ 50 kg (male) or ≥ 45 kg (female)
- BMI within 19～26 kg/m2
Exclusion
- History or disease status that may impact the ADME of the study
- Use of any drugs, OTCs, or hebal within 4 weeks of screening
- Drug abuse
- Blood donation
Key Trial Info
Start Date :
March 27 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 17 2018
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04080609
Start Date
March 27 2018
End Date
April 17 2018
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Hospital of Xuhui District
Shanghai, Shanghai Municipality, China, 201203